Effect of Repeated Oral Doses of Avacopan on the Pharmacokinetics (PK) of a Single Dose of Simvastatin

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-28

Study Completion Date

2022-08-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this clinical study is to evaluate the effect of repeated oral doses of avacopan (30 mg and 60 mg twice daily approximately 12 hours apart \[BID\]) given under fed conditions on the PK of a single dose of simvastatin (40 mg) in healthy volunteers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment

NCT06004934

Hepatic Impairment

COMPLETED PHASE1

Study Evaluating the Pharmacokinetics of the Potential Drug Interaction Between CYP2C9 Inhibitor and Substrate

NCT00369304

Healthy Subjects

COMPLETED PHASE1

Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD0780

NCT06576765

Hepatic Impairment

COMPLETED PHASE1

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

NCT01516047

Hepatic Impairment

COMPLETED PHASE1

Study to Evaluate the Effect of Multiple-Dose Ritlecitinib on the Pharmacokinetics (PK) of Tolbutamide

NCT05097716

Healthy Volunteers

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1: Avacopan and Simvastatin

A single dose of 40 mg simvastatin will be given orally in the morning on Day 1 and Day 10. The Day 10 dose of simvastatin will be co-administered with the morning dose of avacopan. On Days 3 through 11, avacopan will be given orally at 30 mg BID.

Group Type EXPERIMENTAL

Avacopan

Intervention Type DRUG

Orally via capsules

Simvastatin

Intervention Type DRUG

Orally via tablets

Arm 2: Avacopan and Simvastatin

A single dose of 40 mg simvastatin will be given orally in the morning on Day 1 and Day 10. The Day 10 dose of simvastatin will be co-administered with the morning dose of avacopan. On Days 3 through 11, avacopan will be given orally at 60 mg BID.

Group Type EXPERIMENTAL

Avacopan

Intervention Type DRUG

Orally via capsules

Simvastatin

Intervention Type DRUG

Orally via tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avacopan

Orally via capsules

Intervention Type DRUG

Simvastatin

Orally via tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CCX168

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female adults, 18-55 years of age, inclusive.
2. Body mass index (BMI) is 18.5 to 29.9 kg/m\^2.
3. Negative result of the human immunodeficiency virus (HIV) screen, the hepatitis B screen, the hepatitis C screen, and the QuantiFERON®-TB Gold test.
4. A female participant is eligible to participate if she is of:

1. Non-childbearing potential defined as pre-menopausal females with a documented bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy (removal of the ovaries) or hysterectomy; hysteroscopic sterilization, or post-menopausal defined as ≥12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone \[FSH\] in the post-menopausal range is confirmatory). Documented verbal history from the participant is acceptable for all of the criteria stipulated above.
2. Child-bearing potential and agrees to use effective contraception methods from the signing of informed consent until 120 days after the last dose of study treatment.
3. Lactating but willing to stop breast feeding prior to the first dose of study treatment until 120 days after the last dose of study treatment.
5. Female participants must agree not to donate ova starting at Screening and for 120 days after the final study drug administration.
6. Male participants must agree to use highly effective contraception methods. This criterion must be followed from the time of the first dose of study treatment until 120 days after the last dose of study treatment.
7. Male participants must agree not to donate sperm starting from the time of the first dose of study treatment and for 120 days after the final study drug administration

Exclusion Criteria

9. Willing and able to provide written Informed Consent and to comply with the requirements of the study protocol.

1. Women who are pregnant, breastfeeding, or have a positive serum pregnancy test at Screening or on Study Day -1 or women who desire to begin a family or breastfeed during the full length of the study.
2. Expected requirement for use of any medication (with the exception of continued use by female participants of hormonal contraceptives in accordance with a regimen that has been stable for at least the three months prior to Screening and post-menopausal females using estrogen replacement therapy) from Screening through the end of the study.
3. History within the 60 days prior to the first administration of Investigational Product (IP) of use of cannabis, tobacco and/or nicotine-containing products.
4. History of drug abuse (either illicit or prescription) within two years prior to first administration of IP.
5. History of alcohol abuse at any time in the past five years from Screening.
6. History or presence of any form of cancer within the 5 years prior to screening, with the exception of excised basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ such as cervical or breast carcinoma in situ that has been excised or resected completely and is without evidence of local recurrence or metastasis.
7. History or presence of any medical condition or disease or laboratory abnormality which, in the opinion of the Investigator, may place the participant at unacceptable risk for study participation.
8. Donated or lost more than 50 mL of blood or blood products within 56 days prior to screening, or donated plasma within 7 days of randomization.
9. Hemoglobin less than the lower limit of normal or recent history (6 months prior to first dose) of iron deficient anemia.
10. Received a live vaccine or a vaccine for coronavirus 19 disease (COVID-19) within 4 weeks prior to Screening
11. Current or recent COVID-19 infection defined as:

1. positive result of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-V2) test at screening or Day-1, or
2. symptomatic COVID-19 infection within 30 days prior to Day-1, or
3. continuing COVID-19 long haul symptomatology regardless of when the initial COVID-19 infection occurred
12. Known hypersensitivity to avacopan or inactive ingredients of the avacopan capsules (including gelatin, polyethylene glycol, or Cremophor).
13. Participated in any clinical study of an Investigational Product within 30 days or of 5 half-lives prior to randomization.
14. Participant has any evidence of hepatic disease; aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), alkaline phosphatase, or bilirubin \> the upper limit of normal during screening and Day -1.
15. Participant has any evidence of renal impairment, defined as estimated glomerular filtration rate (eGFR) \<90 mL/min/1.73 m\^2 during screening or Day-1
16. Participant's urine tested positive at Screening and/or on Study Day -1 for any of the following: opioids, opiates, amphetamines, cannabinoids, benzodiazepines, barbiturates, cocaine, cotinine, or alcohol (Breathalyzer test allowed for alcohol).
17. Use of alcohol-, caffeine-, or xanthine-containing products within 1 week prior to Day -1.
18. Participant has any evidence of gastro-intestinal disease by exam or history (not including appendectomy or hernia) which could interfere with oral absorption, digestion, or uptake. Participants with cholecystectomy should be excluded.
19. Use of any prescription medications (with the exception of hormonal contraceptives and hormonal therapy), over-the-counter nonsteroidal anti-inflammatory drugs, herbal preparations, St. John's Wort or consumption of grapefruit juice, grapefruit, or Seville oranges within 14 days before Day 1 (first dose).
20. Use of over-the-counter medications, vitamins, or supplements (including omega-3 fish oils) within 7 days before Day 1 (first dose)
21. Participants taking strong cytochrome P450 (CYP)3A4 inducers (e.g., phenytoin, fosphenytoin, rifampin, carbamazepine, St. John's Wort, nevirapine, pentobarbital, primidone, rifapentine, enzalutamide, lumacaftor, mitotane, apalutamide, quinine, rimexolone, rifaximin, rifamycin, topiramate, oxcarbazepine) or moderate CYP3A4 inducers (e.g., bosentan, efavirenz, etravirine, modafinil, dexamethasone, etravirine, nafcillin, dabrafenib, methotrexate, bexarotene, mifepristone) within 2 weeks prior to Day 1.
22. Participants taking strong CYP3A4 inhibitors (e.g., boceprevir, clarithromycin, conivaptan, grapefruit juice or grapefruit, Seville oranges, indinavir, itraconazole, ketoconazole, lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin and voriconazole) within 2 weeks prior to Day 1.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes